FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208423090> ?p ?o ?g. }

• W3208423090 endingPage "S125" @default.
• W3208423090 startingPage "S124" @default.
• W3208423090 abstract "Purpose/Objective(s)Thoracic radiotherapy (TRT) is a mainstay treatment for locally advanced non-small cell lung cancer (LA-NSCLC). Mean heart dose (MHD) and left anterior descending (LAD) receiving ≥15 Gy (LADV15) was shown to predict major adverse cardiac events (MACE) in LA-NSCLC patients receiving TRT. We aim to develop a clinically applicable MACE risk prediction score model, including both cardiac dosimetric and baseline risk factors.Materials/MethodsRetrospective data from 748 consecutive patients with LA-NSCLC treated with curative intent between November 1998 to December 2013 were included. The data was split based on diagnosis dates to allow external validation. Model development was performed on 500 consecutive patients diagnosed before December 2010 using multivariable Cox-proportional hazard model; backward elimination scheme (α = 0.05) was used to select the predictors for the final model. Potential predictors were selected a priori based on prior literature: age, pre-existing coronary heart disease (CHD), Framingham Risk, hypertension (HTN), MHD, LADV15, intensity modulated RT (IMRT) use, and interaction between CHD and LADV15 (CHD:LADV15). Model performance was assessed by the Harrell's c-index and internally validated using leave-one out cross validation (LOOCV). The model was applied to the remaining 248 consecutive patients from the initial cohort as the external validation “test” dataset.ResultsThe development and test cohorts had median age 64 vs 66 years (P = 0.02), 51.0 vs. 50.4% females (P = 0.88), and 89.4 vs 89.1% stage III cancer (P = 0.91). The final model incorporated CHD, HTN, LADV15, and CHD:LADV15 (β coefficients: 2.703, 1.129, 0.043, -0.047; all P < 0.001; c-index 0.773). LOOCV Pseudo R2 = 0.0195. The c-index on the external test dataset was 0.727. Actuarial 3-year MACE rates were 10.7% for development cohort and 15.4% for test cohort. Stratifying development cohort patients into terciles based on MACE risk prediction scores yielded 3-year MACE rates of 0%, 5.7%, and 25.6% for lowest to highest risk-terciles, respectively; among test cohort, the 3-year MACE rates were 4.9%, 10.5%, and 31.9%. Respectively, the 3-year overall survival rates for lowest to highest MACE risk-terciles were 47.3%, 35.2%, and 32.8% among development cohort, and 52.3%, 43.9% and 30.6% within test cohort (both Log-rank P < 0.05).ConclusionThe 3-year MACE rates spans 5% to 32% from lowest to highest risk groups. Both LADV15 and pre-existing cardiac risk factors are important in predicting MACE risk post-TRT. MACE risk score was associated with survival. This tool has the potential to estimate personalized LADV15 constraints based on patient risk factors and acceptable MACE risk thresholds (e.g., 5-10%), thus may help identify patients who may benefit most from the application of advanced RT techniques to further reduce LAD dose as a modifiable risk factor during RT planning. Thoracic radiotherapy (TRT) is a mainstay treatment for locally advanced non-small cell lung cancer (LA-NSCLC). Mean heart dose (MHD) and left anterior descending (LAD) receiving ≥15 Gy (LADV15) was shown to predict major adverse cardiac events (MACE) in LA-NSCLC patients receiving TRT. We aim to develop a clinically applicable MACE risk prediction score model, including both cardiac dosimetric and baseline risk factors. Retrospective data from 748 consecutive patients with LA-NSCLC treated with curative intent between November 1998 to December 2013 were included. The data was split based on diagnosis dates to allow external validation. Model development was performed on 500 consecutive patients diagnosed before December 2010 using multivariable Cox-proportional hazard model; backward elimination scheme (α = 0.05) was used to select the predictors for the final model. Potential predictors were selected a priori based on prior literature: age, pre-existing coronary heart disease (CHD), Framingham Risk, hypertension (HTN), MHD, LADV15, intensity modulated RT (IMRT) use, and interaction between CHD and LADV15 (CHD:LADV15). Model performance was assessed by the Harrell's c-index and internally validated using leave-one out cross validation (LOOCV). The model was applied to the remaining 248 consecutive patients from the initial cohort as the external validation “test” dataset. The development and test cohorts had median age 64 vs 66 years (P = 0.02), 51.0 vs. 50.4% females (P = 0.88), and 89.4 vs 89.1% stage III cancer (P = 0.91). The final model incorporated CHD, HTN, LADV15, and CHD:LADV15 (β coefficients: 2.703, 1.129, 0.043, -0.047; all P < 0.001; c-index 0.773). LOOCV Pseudo R2 = 0.0195. The c-index on the external test dataset was 0.727. Actuarial 3-year MACE rates were 10.7% for development cohort and 15.4% for test cohort. Stratifying development cohort patients into terciles based on MACE risk prediction scores yielded 3-year MACE rates of 0%, 5.7%, and 25.6% for lowest to highest risk-terciles, respectively; among test cohort, the 3-year MACE rates were 4.9%, 10.5%, and 31.9%. Respectively, the 3-year overall survival rates for lowest to highest MACE risk-terciles were 47.3%, 35.2%, and 32.8% among development cohort, and 52.3%, 43.9% and 30.6% within test cohort (both Log-rank P < 0.05). The 3-year MACE rates spans 5% to 32% from lowest to highest risk groups. Both LADV15 and pre-existing cardiac risk factors are important in predicting MACE risk post-TRT. MACE risk score was associated with survival. This tool has the potential to estimate personalized LADV15 constraints based on patient risk factors and acceptable MACE risk thresholds (e.g., 5-10%), thus may help identify patients who may benefit most from the application of advanced RT techniques to further reduce LAD dose as a modifiable risk factor during RT planning." @default.
• W3208423090 created "2021-11-08" @default.
• W3208423090 creator A5001986733 @default.
• W3208423090 creator A5039369605 @default.
• W3208423090 creator A5045648957 @default.
• W3208423090 creator A5051479086 @default.
• W3208423090 creator A5057173854 @default.
• W3208423090 creator A5064724289 @default.
• W3208423090 creator A5067953745 @default.
• W3208423090 date "2021-11-01" @default.
• W3208423090 modified "2023-10-02" @default.
• W3208423090 title "Cardiac Radiation Dose and Patient Risk Factors for Predicting Major Adverse Cardiac Events in Lung Cancer Patients" @default.
• W3208423090 doi "https://doi.org/10.1016/j.ijrobp.2021.07.284" @default.
• W3208423090 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34700445" @default.
• W3208423090 hasPublicationYear "2021" @default.
• W3208423090 type Work @default.
• W3208423090 sameAs 3208423090 @default.
• W3208423090 citedByCount "0" @default.
• W3208423090 crossrefType "journal-article" @default.
• W3208423090 hasAuthorship W3208423090A5001986733 @default.
• W3208423090 hasAuthorship W3208423090A5039369605 @default.
• W3208423090 hasAuthorship W3208423090A5045648957 @default.
• W3208423090 hasAuthorship W3208423090A5051479086 @default.
• W3208423090 hasAuthorship W3208423090A5057173854 @default.
• W3208423090 hasAuthorship W3208423090A5064724289 @default.
• W3208423090 hasAuthorship W3208423090A5067953745 @default.
• W3208423090 hasBestOaLocation W32084230901 @default.
• W3208423090 hasConcept C11783203 @default.
• W3208423090 hasConcept C126322002 @default.
• W3208423090 hasConcept C164705383 @default.
• W3208423090 hasConcept C207103383 @default.
• W3208423090 hasConcept C2776256026 @default.
• W3208423090 hasConcept C2779134260 @default.
• W3208423090 hasConcept C2780400711 @default.
• W3208423090 hasConcept C2780739214 @default.
• W3208423090 hasConcept C44249647 @default.
• W3208423090 hasConcept C500558357 @default.
• W3208423090 hasConcept C50382708 @default.
• W3208423090 hasConcept C71924100 @default.
• W3208423090 hasConcept C72563966 @default.
• W3208423090 hasConceptScore W3208423090C11783203 @default.
• W3208423090 hasConceptScore W3208423090C126322002 @default.
• W3208423090 hasConceptScore W3208423090C164705383 @default.
• W3208423090 hasConceptScore W3208423090C207103383 @default.
• W3208423090 hasConceptScore W3208423090C2776256026 @default.
• W3208423090 hasConceptScore W3208423090C2779134260 @default.
• W3208423090 hasConceptScore W3208423090C2780400711 @default.
• W3208423090 hasConceptScore W3208423090C2780739214 @default.
• W3208423090 hasConceptScore W3208423090C44249647 @default.
• W3208423090 hasConceptScore W3208423090C500558357 @default.
• W3208423090 hasConceptScore W3208423090C50382708 @default.
• W3208423090 hasConceptScore W3208423090C71924100 @default.
• W3208423090 hasConceptScore W3208423090C72563966 @default.
• W3208423090 hasIssue "3" @default.
• W3208423090 hasLocation W32084230901 @default.
• W3208423090 hasLocation W32084230902 @default.
• W3208423090 hasOpenAccess W3208423090 @default.
• W3208423090 hasPrimaryLocation W32084230901 @default.
• W3208423090 hasRelatedWork W2002781300 @default.
• W3208423090 hasRelatedWork W2020050573 @default.
• W3208423090 hasRelatedWork W2033214864 @default.
• W3208423090 hasRelatedWork W2061642979 @default.
• W3208423090 hasRelatedWork W2077717509 @default.
• W3208423090 hasRelatedWork W2089715561 @default.
• W3208423090 hasRelatedWork W2213857236 @default.
• W3208423090 hasRelatedWork W2572837865 @default.
• W3208423090 hasRelatedWork W2888172258 @default.
• W3208423090 hasRelatedWork W3146182361 @default.
• W3208423090 hasVolume "111" @default.
• W3208423090 isParatext "false" @default.
• W3208423090 isRetracted "false" @default.
• W3208423090 magId "3208423090" @default.
• W3208423090 workType "article" @default.